StockData
KIDSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

ORTHOPEDIATRICS CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$22.03+0.08 (+0.36%)

Close on Oct 19, 2026

Market cap
$529.79M
P/E (TTM)
–
Dividend yield
–

About Orthopediatrics

Surgical & Medical Instruments & Apparatus, SIC 3841

OrthoPediatrics Corp. is a medical device company that develops, manufactures, and markets anatomically appropriate implants, surgical instruments, and specialized bracing products for children with orthopedic conditions. The company also provides non-surgical clinical care through a network of orthotic and prosthetic clinics. Its offerings address three primary categories: trauma and deformity correction, scoliosis, and sports medicine. OrthoPediatrics designs its systems to accommodate pediatric anatomy and protect children's growth plates, serving pediatric orthopedic surgeons, caregivers, and pediatric hospitals.

The company is headquartered in Warsaw, Indiana. It sells its systems in the United States and across more than 75 international countries, operating direct sales channels, independent agencies, and stocking distributor networks. Additionally, the company maintains operating entities and facilities in multiple countries, including warehouses in Australia, Germany, and the Netherlands, alongside orthotic and prosthetic clinics in various United States locations and Ireland.

Summary of the business section of Orthopediatrics's latest annual report, written by StockData.

Company profile

Company

Legal name
ORTHOPEDIATRICS CORP
Founded
2006
Headquarters
Warsaw, IN
Address
2850 Frontier Drive 46582
Phone
(574) 268-6379
Employees
602, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Indianapolis, Indiana

Stock & identifiers

Ticker
KIDS
Exchange
Nasdaq
IPO date
Oct 12, 2017
Shares outstanding
26M, Aug 4, 2026
Public float
$362.50M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1425450
CUSIP
68752L100
ISIN
US68752L1008
LEI
5493000KUTPFGOPAT717
EIN
26-1761833

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
David R. BaileyPresident and CEO, Director417,160
Fred HiteCOO and CFO, Director277,477
Daniel J. GerritzenGeneral Counsel and Secretary147,054
Gregory A. OdlePresident of Scoliosis187,735
Joseph W. HauserPres. Trauma & Def. Correction194,767
David R. PelizzonDirector6,246,148
Kelly Laine FischerDirector15,781
Mark C. ThrodahlDirector201,814
Samuel D. RiccitelliDirector31,859
(Reynolds) Marie C. InfanteDirector31,202
Bryan W. HughesDirector32,663
Jimmy Duane McDonaldDirector24,568
George Sinclair Mitchell DyerDirector24,568
Harold RufDirector22,237
Terry D. SchlotterbackDirector29,165

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
David RBailey
$3.33M$1.92M$1.84M$30$75000
FY2024
David RBailey
$3.66M$2.47M$1.88M$56$75000
FY2023
David RBailey
$2.72M$2.21M$1.52M$79$72000
FY2022
David RBailey
$1.28M$826.32K$1.09M$96$75000
FY2021
David RBailey
$906.05K$1.46M$784.91K$145$100000
FY2021
Mark C.Throdahl
$718.03K$1.38M$784.91K$145$100000

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 602 full-time employees, 43 of whom were engaged in research and development and 109 of whom were engaged in sales and marketing.”

Corporate history

Events identified from SEC filings